NEW YORK, April 04, 2018 -- Global Tissue Engineered Skin Substitutes Market was valued at USD 628.31 million in 2017 and is expected to reach USD 1.39 billion by 2026, at a CAGR of 9.3% from 2018 to 2026. Nowadays Chronic wounds and extensive skin loss have become serious problem globally. Even if injured epidermis is normally able to self-renew, deep injuries can cause negative regulation of the wound healing cascade, leading to chronic wound formation. Skin-autografting surgical procedures are often limited by the poor availability of healthy tissue, whereas the use of non-self-tissues for allografts presents some severe risks. Tissue-engineered skin substitutes have recently become viable as a suitable alternative to auto- and allografts. However, biologists, biochemists, and technical engineers are still struggling to produce complex skin substitutes that can readily be transplanted in large quantities. The ambitious goal is now to construct a dermoepidermal substitute that rapidly vascularizes and optimally supports a stratifying epidermal graft on a biodegradable matrix.
Skin substitutes can be broadly divided into cellular and acellular devices, yet within these categories, each product has its own unique composition and mechanism for promoting healing. Here we summarize the characteristics and indications of cellular and acellular matrices commonly used in wound care with the most evidence supported by randomized control trials and prospective studies. This review aims to provide dermatologists and other wound care clinicians with a helpful guide on how to approach skin substitutes, from preparing the wound bed for application, to making the proper selection for patients’ individual wounds.
Tissue-engineered skin substitutes represent an efficient way of meeting the deficiency in donor-skin-graft supplies. They are able to protect damaged regions from fluid loss and contamination and promote release of cytokines and growth factors at the wound site, accelerating the wound-healing processes. They also act as a temporary protective cover of the wound bed during healing. More complex 3D models have recently been developed that use cocultures of different kinds of cells, with the goal of enhancing engineered tissues’ similarity to their natural counterpart. Melanocytes have been introduced to recreate the natural pigmentation process in vitro. Different skin combinations of keratinocytes and melanocytes from Caucasian and Negroid donors confirmed that pigmentation is under the control of melanocytes, whereas keratinocytes play an antioxidant defensive role. Sunlight can cause erythema and melanoma; tissue-engineered skin substitutes may be used as easily manageable in vitro systems in studies aiming to produce new photoprotective agents.
Get Free Report Sample: https://www.profsharemarketresearch.com/sample/tissue-engineered-skin-substitutes-market-report-sample/
Tissue Engineered Skin Substitutes Market: Competitive Analysis
Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study constitutes of following key players in Tissue Engineered Skin Substitutes Market:
- Amarantus BioScience Holdings
- Acelity L.P., Inc.
- BSN medical
- Integra LifeSciences Corporation
- Medtronic (Covidien)
- Molnlycke Health Care
- Smith & Nephew plc
- Organogenesis, Inc
Get Customized Report Copy: https://www.profsharemarketresearch.com/enquiry/tissue-engineered-skin-substitutes-market-report-enquiry/
Tissue Engineered Skin Substitutes Market: Procedure Type
- Cellular Allogeneic
- Acellular
- Cellular Autologous
Tissue Engineered Skin Substitutes Market: Applications
- Burn Injury
- Diabetic
- Vascular Ulcer
- Chronic wound
Tissue Engineered Skin Substitutes Market report delivers comprehensive analysis of :
- Market Forecast for 2018-26
- Market growth drivers
- Challenges and Opportunities
- Emerging and Current market trends
- Market player Capacity, Production, Revenue (Value)
- Supply (Production), Consumption, Export, Import analysis
- End user/application Analysis
Buy Report: https://www.profsharemarketresearch.com/buy/tissue-engineered-skin-substitutes-market-report-buy-mu/
Contact Us:
Mia Cox,
Email- [email protected]
Tel- 1-877-797-7295


Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Anta Sports Expands Global Footprint With Strategic Puma Stake
Samsung Electronics Shares Jump on HBM4 Mass Production Report
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Washington Post Publisher Will Lewis Steps Down After Layoffs
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Amazon Explores AI Content Marketplace With Media Publishers
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 



